The funding builds on more than $1.7 million already awarded to the firm, which is building a diagnostic for characterizing patients in clinical trials.
The company aims to commercialize the platform and related services by late 2018.
The SBIR Phase 1 award will go toward developing a test using immuno-PCR technology to detect toxins in medical marijuana.
The company is working with the University of Florida Health Cancer Center to validate its RadTox QuantiDNA test as a monitor of cfDNA in patient plasma.
The company has received grant funding for diagnostic development projects, and is also seeking its first pharma service customers to provide nearer-term revenue.
The funding will go towards developing the PathMap companion diagnostic technology, based on the firm's SnapPath platform.
Proposed increases to small business programs touch off fight between business and research groups, ScienceInsider reports.
The genetic screening firm validated the modifications with a Phase I SBIR grant from NIH and is seeking a Phase II grant to target critical protein domains.
The firm said the method could lead to more studies on the genetic determinants of disease for people of mixed or non-European ethnic backgrounds.
The companies are combining GMSbiotech's proprietary microarray platform with soluble human leukocyte antigen proteins produced by Pure Protein.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.